1. Introduction {#sec1}
===============

Women can experience menopausal symptoms beginning in their mid-to-late forties \[[@B1]\]. It has been reported that almost 80% of women in western countries and more than 60% of Chinese women suffer from menopausal problems \[[@B2]--[@B4]\]. An American survey reports that approximately 25% of women require treatment \[[@B5]\]. Menopausal symptoms can last for 4-5 years or longer and can even be found in 9% of 72-year-old women \[[@B1], [@B3], [@B6], [@B7]\]. Menopausal syndrome not only has an impact on women\'s quality of life but also is associated with other health problems, for example, cardiovascular disease and osteoporosis in old age \[[@B8]--[@B10]\].

Clinical manifestations of menopausal syndrome have a multivariate feature, including vasomotor episodes, urogenital problems, sleep disturbance and mood disorders, uterine bleeding, somatic symptoms, vertigo and headaches, palpitations, skin formication, and sexual dysfunction \[[@B8], [@B11]--[@B16]\]. Among them, vasomotor symptoms, vaginal dryness, and sleep disturbance are most frequent and thus regarded as the most relevant problems, followed by mood symptoms and urinary complaints \[[@B3]\].

Hormone therapy is taken to be the most effective treatment for menopausal syndrome, but various disadvantages and side effects have been reported, including increased risk of breast and ovarian cancer, endometrial hyperplasia and carcinoma, stroke, and venous thromboembolism, especially for long-term therapy \[[@B17]--[@B25]\]. Furthermore, a significant proportion of menopausal women have contraindications to or are unwilling to use hormone therapy. Therefore, not only patients but also physicians are increasingly interested in complementary therapies using natural products with good effectiveness and fewer side effects \[[@B26], [@B27]\]. In USA, 82% physicians recommend herbal remedies to their menopausal patients \[[@B28]\].

Chinese herbal medicine (CHM), one of these natural product treatments with less side effect, has been widely used to disperse menopausal problems in China and other Asian countries \[[@B29]--[@B36]\]. However, in western society, the evidence of its efficacy is seen as unconvincing \[[@B3], [@B37]--[@B39]\]. Though there has been a large number of case reports and pilot clinical trials with various prescriptions in China in the past decades, they do not provide comparable, measurable, and reproducible evidence for efficacy of the treatments. On the other hand, randomized double-blind controlled trials in western medicine framework demand and favor homogeneity of participants, standardization of intervention, and quantitative measurements but lack consideration for Chinese medical Zheng features.

Zheng differentiation (pattern differentiation, *辨证*), a syndrome stratification according to traditional Chinese medicine (TCM) diagnosis methods, plays the central role in the concept and practice of TCM. The logic of this TCM diagnosis differs fundamentally from that of the western scientific thinking. According to the TCM rationale, menopausal syndrome are caused by imaginary dysfunction of several organs such as kidney, liver, heart, and spleen, as well as imaginary pathogenic products induced by that dysfunction such as excessive fire, blood stasis, qi stagnation, and phlegm-dampness. The consequence is loss of coordination of qi and blood, disharmony of cold and heat, and imbalance of yin and yang ([Figure 1](#fig1){ref-type="fig"}) \[[@B40]--[@B44]\]. A Zheng differentiation of a menopausal case can be, for example, "aging-induced kidney dysfunction" or "kidney-based organ dysfunction" \[[@B40]\]. TCM therapies, both standardized and individualized, are adapted according to this kind of stratification. Efficacy of CHM on menopausal syndrome is thus also expected to rely on Zheng stratification \[[@B31], [@B45]--[@B47]\].

In this study, we evaluated more than 2000 published studies on efficacy of CHM for menopausal syndromes and critically analyzed 23 fit to our criteria, focusing on diagnosis, outcome measure, efficacy and side effects/adverse effects. We further discuss the role of Zheng-differentiation.

2. Materials and Methods {#sec2}
========================

2.1. Databases and Search Strategy {#sec2.1}
----------------------------------

Three Chinese electronic databases including VIP Database for Chinese Technical Periodicals (VIP), Chinese National Knowledge Infrastructure (CNKI), Chinese Biomedical Literature Database (CBM), and two major international electronic databases (Cochrane Library and MEDLINE) were searched. Specific search strategy for literatures was established for each of the five databases. The search strategy and terms for VIP, CNKI, and CBM were translated from Chinese. The search strategy for MDELINE was developed by modifying a published protocol of CHM for menopausal symptoms from Cochrane library \[[@B48]\]. Details of the search strategies and the abbreviation list are provided in the supplementary information available online at doi:10.1155/2012/568106.

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Randomized controlled trials of orally taken Chinese herbal medicine, including powders, liquid, pills, tablets, and capsules for treating physical or psychological menopausal symptoms published in Chinese or English were included. Kampo medicine (Japanese branch of traditional Chinese medicine), employing similar prescriptions of Chinese herbal medicine, was also considered \[[@B49]--[@B51]\]. Menopause included spontaneous ones and those induced by surgery, chemotherapy or radiotherapy. Control groups contained placebo, hormone therapy, other alternative medicine (e.g., SSRIs (selective serotonin reuptake inhibitors), oryzanol), acupuncture, and no treatment. Only studies with outcomes measured by quantitative questionnaires or participant\'s symptom diaries for menopausal symptoms were included ([Figure 2](#fig2){ref-type="fig"}).

Exclusion criteria were (1) using natural products such as soybean products, black cohosh (*Cimicifuga racemosa*), red clover (*Trifolium pratense*), St. John\'s wort (*Hypericum perforatum*), and other non-Chinese herbs, (2) combined interventions of Chinese herbal medicine with other treatments (hormone therapy, vitamins, minerals, cod-liver oil, evening primrose oil, acupuncture, acupoint, nutrition consultation, etc.), (3) using another CHM remedy as a comparator, (4) participants younger than forty, (5) interventions of less than two weeks, and (6) postmenopausal osteoporosis ([Figure 2](#fig2){ref-type="fig"}).

2.3. Evaluation {#sec2.3}
---------------

Two independent specialists (Lian-Wei Xu and Man Jia) assessed the abstract and full-text literatures of all potential eligible trials meeting the inclusion criteria and summarized using data extraction forms from the selected studies. One of the two reviewers completed the forms which were subsequently confirmed by the others. Some of missing information was sought by contacting authors of the corresponding publications. The methodological quality of studies was evaluated using Jadad scale \[[@B52]\].

"Efficacy" for a CHM intervention is defined as (1) significant improvement compared to placebo or (2) similar improvement compared to standard therapy for either total scores or subscales of major relevant symptoms such as hot flushes and psychological parameters.

3. Results {#sec3}
==========

3.1. Study Quality {#sec3.1}
------------------

A total of 2036 randomized controlled trials (RCTs) in Chinese databases and 68 in English databases were retrieved ([Figure 2](#fig2){ref-type="fig"}). Majority of studies were not blinded and many lacked adequate controls or comparators. Also lack of consideration for dropouts and lack of standardized outcome measures are frequent. The remaining total of 23 studies consisting of 9 Chinese and 14 non-Chinese met the inclusion and exclusion criteria and were further evaluated in following analysis \[[@B34], [@B53]--[@B74]\]. Jadad score varied from 1 to 4 (mean = 2.8) for the 9 Chinese papers and 2 to 5 (mean = 3.7) for the 14 non-Chinese papers ([Table 2](#tab2){ref-type="table"}).

3.2. Diagnosis and Zheng Differentiation {#sec3.2}
----------------------------------------

In all these 23 RCTs, menopausal syndrome was diagnosed according to the standardized western medical criteria. Seven Chinese studies and one Netherlandish study further stratified the participants according to the TCM Zheng diagnosis (Figures [2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}, [Table 1](#tab1){ref-type="table"}) \[[@B67]--[@B74]\]. Seven of studies considered yin deficiency and three specially mentioned kidney deficiency. These Zheng differentiation considered dysfunction of kidney, liver, and imbalanced pathogenic factors excessive liver qi, excessive fire, and blood stasis. The main Zhengs were (1) yin deficiency and excessive fire Zheng, (2) yin deficiency and excessive liver qi Zheng, (3) kidney (yin or yang) deficiency Zheng, and (4) spleen-kidney deficiency with blood stasis Zheng. Among these eight trials, one included all patients meeting western menopausal diagnosis and treated them individually according to the differential Zheng-differentiation \[[@B67]\]. The other seven included only patients meeting certain Zheng-differentiation for which the respective herbal mixture was formulated \[[@B68]--[@B74]\]. None of the studies described details of procedure of the Zheng-differentiation.

3.3. CHM Interventions and Control {#sec3.3}
----------------------------------

One study used hydrophilic concentration of individualized CHM prescribed according to the Zheng-differentiation of each participant \[[@B67]\]. All the other 22 used standard patented Chinese medicine of classical, modified classical or empirical prescriptions or single herb in granules, capsules, oral liquid, powder, or tablets ([Table 1](#tab1){ref-type="table"}). Nineteen trials used mixed herbs while the other four used single herb ([Figure 3](#fig3){ref-type="fig"}, [Table 1](#tab1){ref-type="table"}).

The duration of the interventions was between eight weeks and two years ([Table 1](#tab1){ref-type="table"}). One study had followup until four weeks after termination of the treatment \[[@B67]\].

Fifteen studies had placebo control, 9 used hormone therapy (Premelle, Premarin plus Medroxyprogesterone, Tibolone, or estradiol valerate), Paroxetine (SSRI), or vitamin E plus oryzanol as positive comparators ([Table 1](#tab1){ref-type="table"}).

3.4. Outcome Measure {#sec3.4}
--------------------

All the 23 included trials used quantitative methodology to score and measure the extent of the menopausal symptoms and quality of life ([Table 1](#tab1){ref-type="table"}). Kupperman Index and modified Kupperman Index are the most frequently used systematic measures (in 11/23 studies), especially in Chinese studies (8/9). Five Chinese trials employed the Chinese Medical Symptoms Scale corresponding to the TCM Zheng-differentiation. Other studies applied various scales including Greene Climacteric Scale, Menopause Rating Scale, Menopause Specific Quality of Life, Short-Form 36 Health Survey (SF-36), Pittsburgh Sleepiness Quality Scale, and Hamilton Depression Scale. Some of the trials provided scores of each symptom or domain separately while others gave the total scores for these standardized questionnaires. Six non-Chinese studies measured vasomotor symptoms by patient diary.

3.5. Efficacy {#sec3.5}
-------------

All 9 Chinese and 8/14 non-Chinese studies reported positive effects of CHM while the other 6 non-Chinese studies did not find effectiveness. Positive effects included significant improvement (in total scores or in subscales of major relevant symptoms) compared to placebo and similar improvement compared to standard hormone therapy or other recognized alternative medicine. Reduction of hot flushes was the most frequently reported positive effect followed by improvement in total scores, benefits in depression, and other psychological measures. Generally, non-Chinese studies reported more details than Chinese ones.

Among the 9 Chinese studies, 5 employed placebo, 3 employed HRT, and one used Vit E plus oryzanol as positive comparators \[[@B61], [@B62], [@B68]--[@B74]\]. Majority of the Chinese studies reported only total scores of questionnaires but no data for subscales. Most studies declared that CHM improved scores of menopausal symptoms in comparison to placebo or reached similar effect of that of positive comparators (oryzanol or HRT). Only Wang et al. reported rather confusing results that CHM reduced total score of modified Kupperman index in the 8th week but not in the 12th week of the treatment \[[@B70]\].

One non-Chinese study observed significant improvement for Greene\'s scales for the CHM treatment group in comparison to baseline. However, most of these positive effects were significantly weaker than those of the Paroxetine treatment. The authors, thus, could not reach a conclusion for the efficacy of the CHM \[[@B57]\].

A total of 5 non-Chinese studies reported no efficacy ([Figure 3](#fig3){ref-type="fig"}). All these 5 studies employed placebo or no treatment as the comparators. Four studies reported substantial but similar improvements in both CHM and placebo groups \[[@B34], [@B53], [@B55], [@B56]\]. One did not find improvement at all in five major domains in CHM, HRT, and no treatment groups \[[@B54]\].

Eight out of the 9 Chinese studies and one non-Chinese study stratified patients according to their TCM-Zheng \[[@B67]\]. For example, Kwee et al. reported that individualized CHM for menopausal patients with Zheng-differentiation led to 29% reduction of average score of hot flushes compared to placebo \[[@B67]\]. In the study of 442 patients with yin deficiency and excessive liver qi, CHM mixture Jing Qian Ping granules significantly improved total scores of modified Kupperman Index and Chinese Medical Symptoms Scale compared to placebo ([Table 1](#tab1){ref-type="table"}) \[[@B71]\].

Two of the 4 studies with single herb reported efficacy while the other two did not ([Figure 3](#fig3){ref-type="fig"}).

A meta-analysis for efficacy of CHM was not feasible due to the variety of measurements of outcomes and the heterogeneity of the trials.

3.6. Safety and Adverse Effects {#sec3.6}
-------------------------------

Eight trials systematically examined the endometrial thickness after the interventions and none of them found abnormal increase of thickness of endometrium by CHM. In contrast, increase of thickness of endometrium was reported in patients receiving hormone therapy which was used as a positive comparator in one study \[[@B62]\].

Nineteen trials monitored standard physiological functions and investigated adverse events or side effects of CHM ([Table 1](#tab1){ref-type="table"}) \[[@B34], [@B53]--[@B61], [@B63]--[@B73]\]. Six trials (32%) reported no serious side effects or adverse events. Six of the remaining thirteen trials reported some adverse events which were, however, similar to those in corresponding placebo groups. Only one study reported more diarrhea in CHM group than in placebo ([Table 1](#tab1){ref-type="table"}). The most common side effect was gastrointestinal symptoms including abdominal bloating or pain, epigastric discomfort, and stomach disorder in 8, followed by diarrhea in 7, headache in 4, nausea in 3, breast distension or pain in 2, abnormal vaginal bleeding in 2/19, and dizziness in 2 studies.

Only 10 severe adverse events were reported by three trials, among a total of 1837 participants ([Table 2](#tab2){ref-type="table"}). One adverse event was per rectum bleeding, which may be possibly associated to the hot feature of Dang Gui Bu Xue Tang (DBT) \[[@B55]\]. Wiklund et al. reported 7 severe adverse events and stated that one of them was likely related to the CHM medication. However, no detailed information was available regarding feature of this event \[[@B58]\]. Two other serious adverse events were found in high dose of CHM of Grady et al.\'s trial. One was idiopathic pancreatitis and the other one had occurred before the trial \[[@B59]\]. The paper did not mention the relationship between CHM intervention and idiopathic pancreatitis.

The longest trial over two years did not report serious adverse events \[[@B72]\]. None of the other studies investigated long-term side effect.

4. Discussion {#sec4}
=============

4.1. Efficacy, Study Quality and Zheng Differentiation {#sec4.1}
------------------------------------------------------

To date, more than 2000 studies have been carried out concerning efficacy of CHM for menopausal syndrome, mostly in China and published in Chinese journals. However, only very few meet some of the standards of evidence-based medicine. We could only select 9 Chinese and 14 non-Chinese studies for evaluation.

All Chinese studies reported effectiveness for CHM. However, these studies have generally low quality and lacked detailed data. In addition, the fact that Chinese journals traditionally publish only positive results seriously reduces reliability of the reported efficacies.

Non-Chinese studies have generally better quality. However, most of these studies have the drawback of lacking consideration of Chinese medical features, especially Zheng-differentiation, the essential soul of TCM theory and practice. As in western medicine, CHM is also prescribed according to diagnosis which is based on a different way of interpretation and consideration of symptoms and endogenic/exogenic factors in a disordered and disharmonized menopausal female body ([Figure 1](#fig1){ref-type="fig"}). Thus, efficacy of CHM relies on Zheng-differentiation and may be less prominent in non-Chinese studies which do not apply Zheng-differentiation. Authors of a study carried out on American women indeed discussed that the lack of consideration of *sho*(similar to Zheng-differentiation) for participants may have contributed to the negative results \[[@B34]\].

Zheng-differentiation is a basic skill of TCM professionals who, however, often lack experience in randomized, blinded, and placebo-controlled clinical trials meeting the standard of evidence-based medicine in western countries. Cooperation of TCM and western medicine professionals is, thus, desirable for future studies on efficacy of CHM for menopausal in Chinese and non-Chinese females. Such studies will also help elucidating the role of Zheng-differentiation in TCM in general.

4.2. Side Effect and Adverse Events {#sec4.2}
-----------------------------------

An important feature of CHM is the lack of increase of endometrial thickness, a common side effect of hormone therapy \[[@B62]\]. This can be well seen in several of the evaluated studies.

Other side effects of CHM are infrequent and generally mild. Among a total of 1837 treated cases, only ten severe adverse events were reported, though for eight of them there was no evidence of causal relation with the used CHM. Only two adverse events may have been related to the some components of the respective CHM: nausea in one case may be related to Ginseng \[[@B58]\] and per rectum bleeding in another case to the hot nature of Dang Gui Bu Xue Tang \[[@B55]\]. The most frequent side effects were mild gastrointestinal symptoms.

The observation periods of the evaluated studies were generally short (around 12 weeks). Thus, long-term side effects known for CHM remain a central issue for future studies.

5. Conclusion {#sec5}
=============

Large number of studies have been carried out on efficacy of CHM for menopausal syndrome, but most of them lack adequate quality. CHM may be effective for at least some menopausal symptoms while its side effects are likely less than those of hormone therapy. However, all these findings need to be confirmed in further well-designed comprehensive studies which meet the standard of evidence-based medicine and include Zheng-differentiation of TCM. Cooperation of western medical and TCM professionals is essential.

Supplementary Material {#supplementary-material-sec}
======================
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Three Chinese databases, VIP, CNKI, CBM, and two English electronic databases, Cochrane Library, MEDLINE, were searched according to their special searching strategies. The details of the strategies, word strings and abbreviation are provided in the following supplementary information

###### 
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![Illustration of the TCM understanding of menopausal symptoms.](ECAM2012-568106.001){#fig1}

![Number of studies on efficacy of CHM for menopausal syndrome at various stages of retrieval and selection process.](ECAM2012-568106.002){#fig2}

![Classification of the 23 selected trials. The 4 single herb trials are marked at their upper-left corners, the 9 Chinese studies can be identified by the name of the first author in Chinese character. The 15 trials without Zheng differentiation were in boxes with single line and the 8 trials with Zheng differentiation were in italic. Boxes for trials with positive results are shaded. The fifteen trials applied placebo control marked with \*. Others used positive comparators. Numbers in brackets are numbers of cases in CHM treatment/comparison groups.](ECAM2012-568106.003){#fig3}

###### 

Summary of findings of included randomized controlled trials of CHM for menopausal symptoms.

###### 

\(a\)  

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Number of case\              Age (year)\                                         Duration                         Chinese herbal medicine, form and dose                                            Comparator   
                                       treatment/comparison         treatment/comparison                                                                                                                                                                
  ------------------------------------ ---------------------------- --------------------------------------------------- -------------------------------- --------------------------------------------------------------------------------- ------------ -----------------------------------------------------------------------
  Hirata et al.,1997 \[[@B53]\]        35 (4)/36 (6)                52.2 ± 4.0/52.6 ± 6.0                               6, 12, 24 weeks                  Dong quai root, granular powder, 4.5 g/day                                        Yes          No

                                                                                                                                                                                                                                                        

  Woo et al.,2003 \[[@B54]\]           PL: 47 (5)\                  PL: 57.4 ± 4.6\                                     3 months                         *Pueraria lobata* (PL) powder, 100 mg/day                                         No           HRT: Premelle 1\#/day
                                       HRT: 48 (2)\                 HRT: 56.2 ± 4.9\                                                                                                                                                                    
                                       No treatment: 41 (2)         No treatment: 57.2 ± 4.8                                                                                                                                                            

                                                                                                                                                                                                                                                        

  Haines et al.,2008 \[[@B55]\]        50 (5)/50 (11)               52.8 ± 4.9/51.2 ± 4.6                               6 months                         Dang Gui Bu Xue Tang (DBT) capsule 3 g/day                                        Yes          No

                                                                                                                                                                                                                                                        

  Davis et al.,2001 \[[@B56]\]         42 (14)/36 (9)               56.3 (54.3--58.3)/\                                 12 weeks                         CHM granule                                                                       Yes          No
                                                                    54.1 (52.6--55.5)                                                                                                                                                                   

                                                                                                                                                                                                                                                        

  Plotnikoff et al., 2012 \[[@B34]\]   Low: 62 (11)\                Low dose: 53.7 ± 0.38\                              12 weeks                         TU-025 (keishibukuryogan) capsule, 7.5 g/day (low dose), 12.5 g/day (high dose)   Yes          No
                                       High: 57 (13)\               High dose: 53.6 ± 0.49\                                                                                                                                                             
                                       Placebo: 59 (1)              Placebo: 53.3 ± 0.38                                                                                                                                                                

                                                                                                                                                                                                                                                        

  Yasui et al.,2009 \[[@B57]\]         38 (3)/38 (6)                51.4 ± 5.1/50.5 ± 5.4                               6 months                         Kamishoyosan 7.5 g                                                                No           Paroxetine 10 mg/day

                                                                                                                                                                                                                                                        

  Wiklund et al.,1999 \[[@B58]\]       193 (3)/191 (2)              53.3 ± 4.0/53.6 ± 4.0                               16 weeks                         Ginseng extract capsule 200 mg/day                                                Yes          No

                                                                                                                                                                                                                                                        

  Grady et al.,2009 \[[@B59]\]         Low: 71 (1)\                 Low: 53.9 ± 2.6\                                    4, 8, 12 weeks                   \(1\) MF101 powder, 5 g/day \                                                     Yes          No
                                       High: 75 (1)\                High: 53.6 ± 3.0\                                                                    (2) MF101 powder, 10 g/day                                                                     
                                       Placebo: 71 (2)              Placebo: 53.7 ± 2.8                                                                                                                                                                 

                                                                                                                                                                                                                                                        

  Chen et al.,2003 \[[@B60]\]          37 (13)/25 (11)              50.17 ± 3.41/52.14 ± 5.33                           16 weeks                         Jia-Wey Shiau-Yau\                                                                No           Premelle 1^\#^/day^▲▲^
                                                                                                                                                         San (JWSYS), powder, 4 g, tid/day                                                              

                                                                                                                                                                                                                                                        

  *郑* Zheng et al.,2009 \[[@B61]\]    CHM: 30 (0)\                 CHM: 51.40 ± 2.57\                                  4, 8, 12 weeks                   Gengnianle Granule, 10 g, bid/day                                                 Yes          TCM package^▲▲▲^
                                       TCM package: 35 (0)\         TCM package: 51.17 ± 2.82\                                                                                                                                                          
                                       Placebo: 20 (0)              Placebo: 50.65 ± 2.32                                                                                                                                                               

                                                                                                                                                                                                                                                        

  *韦* Wei and Luo,2007 \[[@B62]\]     60 (0)/30 (0)                40--55                                              3 months                         Qianjinbayin 3 g bid/day                                                          No           Premarin 0.625 mg/day + Medroxyprogesterone 6 mg/day (15th--28th day)

                                                                                                                                                                                                                                                        

  Qu et al.,2009 \[[@B63]\]            21 (0)/26 (0)                48.7 ± 8.1/50.4 ± 9.3                               12 weeks                         Gengnianle decoction 200 mL/day                                                   No           Tibolone 2.5 mg/day

                                                                                                                                                                                                                                                        

  Chang et al., 2012 \[[@B64]\]        31 (2)/33 (1)                53.2 ± 5.7/54.1 ± 5.9                               6, 12 weeks                      EstroG-100, 1^\#^ bid/day                                                         Yes          No

                                                                                                                                                                                                                                                        

  Kim et al., 2012 \[[@B65]\]          36 (5)/36 (4)                52.98 ± 3.04/55.01 ± 3.67                           12 weeks                         Red ginseng capsule 1 g tid/day                                                   Yes          No

                                                                                                                                                                                                                                                        

  Hsu et al.,2011 \[[@B66]\]           25 (0)/25 (0)                51.92 ± 2.97/53.08 ± 3.00                           6, 12 months                     Dioscorea extracts 12 mg bid/day                                                  Yes          No

                                                                                                                                                                                                                                                        

  Kwee et al.,2007 \[[@B67]\]          CHM: 10 (1)\                 CHM: 53.2 (51.5--55.0)\                             12 weeks, plus 4-week followup   \(i\) Modified Zhi Bai Di Huang Wan\                                              Yes          Premelle 1^\#^/day
                                       HRT: 11 (0)\                 HRT: 53.6 (50.0--57.3) Placebo: 54.9 (51.6--58.2)                                    (ii) Individualized hydrophilic concentration                                                  
                                       Placebo: 10 (0)                                                                                                                                                                                                  

                                                                                                                                                                                                                                                        

  *陈* Chen et al.,2005 \[[@B68]\]     77 (12)/70 (12)              50.79 ± 4.45/50.43 ± 4.16                           1, 3 months                      Kuntai capsule 2 g tid/day                                                        No           E~2~V 0.5 mg/day^▲▲▲▲^

                                                                                                                                                                                                                                                        

  *楼* Lou et al.,2009 \[[@B69]\]      80 (11)/30 (3)               52.69 ± 3.12/51.85 ± 2.92                           8 weeks                          Xian ling gu bao capsule 3^\#^ bid/day                                            Yes          No

                                                                                                                                                                                                                                                        

  *王* Wang et al.,2006 \[[@B70]\]     CHM: 111 (---)\              No detail^▲^                                        4, 8, 12 weeks                   \(1\) Geng nian ning C:C tid/day for kidney yin deficiency \                      Yes          \(1\) CHM + Chinese medical qing zhi therapy^▲▲▲▲▲^  \
                                       CHM + qing zhi: 105 (---)\                                                                                        (2) Bushen oral liquid, 1 bottle bid/day for kidney yang deficiency                            (2) Chinese medical qing zhi therapy
                                       Qing zhi: 104 (---)\                                                                                                                                                                                             
                                       Placebo: 104 (---)                                                                                                                                                                                               

                                                                                                                                                                                                                                                        

  *吴* Wu et al.,2009 \[[@B71]\]       359 (23)/120 (14)            45--55                                              8 weeks                          Jing qian ping granule 4 g tid/day                                                Yes          No

                                                                                                                                                                                                                                                        

  *李* Li et al.,2009 \[[@B72]\]       188 (53)/189 (96)            48.8 ± 2.93/48.6 ± 2.74                             2 years                          Bushen Zhuanggu granule 100 g bid/day × 6 months, then 100 g/day                  No           Premarin 0.625 mg/day + Medroxyprogesterone 2 mg/day

                                                                                                                                                                                                                                                        

  *李* Li et al.,2008 \[[@B73]\]       72 (0)/36 (0)                49.25 ± 2. 38/49.15 ± 2.68                          3 months                         Gengnianningshentang decoction                                                    No           Vit E 100 mg bid + oryzanol 20 mg tid

                                                                                                                                                                                                                                                        

  *刘* Liu et al.,2011 \[[@B74]\]      30 (5)/30 (4)                50.63 ± 3.8/50.63 ± 4.65                            12 weeks                         Ziyin Jianghuo Fang (ZYJHF) granules                                              Yes          No

                                                                                                                                                                                                                                                        

  Total amount                         1837/1609                    //                                                  /                                /                                                                                 /            /
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

---: did not report.

^▲^Including patients with age from 45 to 55, according to the defined inclusion criteria published by Chinese Ministry of Health, 1997 \[[@B75]\].

^▲▲^Premelle: 1 tablet includes 0.625 mg conjugated oestrogen, 5 mg medroxyprogesterone.

^▲▲▲^TCM package: CHM + Chinese medical psychological therapy + Taiji.

^▲▲▲▲^E~2~V: estradiol valerate.

^▲▲▲▲▲^Chinese medical qing zhi therapy: Chinese medical psychological therapy, *情志疗法*.

/: blanket.

###### 

\(b\)  

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Outcome measure                                                                                                                      Outcomes                                                                                                                                                                                                                                                                                Efficacy                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------
  Hirata et al.,1997 \[[@B53]\]        \(a\) Kupperman Index\                                                                                                               No significant improvement for (a) and (b)                                                                                                                                                                                                                                              /                                                                                                                                                                                                 About 25%--30% reduction for (a) and (b), score of (a) from 19.0 ± 8.4 to 12.2 ± 5.2 (*P* \< 0.001), number of vasomotor episodes per week from 47.3 ± 39.9 to 30.7 ± 21.7 (*P* \> 0.05)                                                                                                                                                                                                                                               No
                                       (b) Diary of number of vasomotor symptoms                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Woo et al.,2003 \[[@B54]\]           \(a\) Menopausal symptoms questionnaire\                                                                                             \*No improvement for majority items of (a) and (b); \*more improvement for cognitive function                                                                                                                                                                                           Similar change for (a), (b), and (c)                                                                                                                                                              \*No improvement for five domains of (a); \*for (b), percentage change 10.0 ± 20.5 for physical functioning, 28.6 ± 67.5 for role physical, 16.5 ± 48.0 for bodily pain, 13.5 ± 69.7 for general health, 25.7 ± 52.8 for vitality, 13.0 ± 58.9 for social functioning, 0.5 ± 82.3 for role emotional, and 13.2 ± 23.0 for mental health; \*percentage increase 3.4 ± 8.5 for (c)                                                       No
                                       (b) Short Form 36 Health Survey\                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
                                       (c) Mini-Mental State Examination (MMSE)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Haines et al.,2008 \[[@B55]\]        \(a\) Self-reported daily diary for vasomotor symptoms (b) Menopause-specific quality of life                                        \*No significant difference for mild, moderate, and severe hot flushes as well as night sweats of (a); \*similar improvement for four domains of (b)                                                                                                                                    /                                                                                                                                                                                                 \*Improvement for number of mild hot flushes from 18.9 ± 23.5 to 8.6 ± 17.1 per month (*P* = 0.002); \*improvement for sexual domain of (b) from 3.49 ± 1.96 to 2.73 ± 1.80 (*P* \< 0.01)                                                                                                                                                                                                                                              No

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Davis et al.,2001 \[[@B56]\]         \(a\) Diary of the frequency of vasomotor symptoms (b) Menopause-specific quality of life                                            \*The frequency of vasomotor symptoms reduced but with similar improvement; \*similar reduction for scores of four domains of (b)                                                                                                                                                       /                                                                                                                                                                                                 \*More than 40% reduction in the frequency of vasomotor symptoms (*P* = 0.001); \*improvement for physical, vasomotor, and sexual domains of (b)                                                                                                                                                                                                                                                                                       No

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Plotnikoff et al., 2012 \[[@B34]\]   \(a\) Daily Mayo Hot Flash Symptom Diary; (b) Greene Climacteric Scale; (c) Pittsburgh Sleepiness Quality Scale                      Similar improvement for (a), (b), and (c) without significant difference (*P* \> 0.05)                                                                                                                                                                                                  /                                                                                                                                                                                                 \*40% Improvement for (a) in low-dosage group, 38% in high-dosage group (*P* \< 0.001); \*significant reduction for the mean scores of (b) (*P* \< 0.001); \*improvement for (c) and its subscales (*P* \< 0.001), except sleep medication use                                                                                                                                                                                         No

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Yasui et al.,2009 \[[@B57]\]         Greene Climacteric Scale                                                                                                             /                                                                                                                                                                                                                                                                                       Less improvement for psychological (*P* = 0.0007), vasomotor(*P* = 0.05)and total score (*P* = 0.0002), no difference for somatic subscore (*P* = 0.167)                                          Improvement for psychological, somatic, and vasomotor subscores and total score (*P* \< 0.0001)                                                                                                                                                                                                                                                                                                                                        Unconcluded

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Wiklund et al.,1999 \[[@B58]\]       \(a\) Psychological general well-being Index; (b) women\'s health questionnaire; (c) visual analogue scales                          \*Slightly better overall symptomatic relief (*P* \< 0.1); \*significant better improvement in depression and well-being subscales (*P* \< 0.05); \*no significant effects for (b) and (c) or the physiological parameters, including vasomotor symptoms                                /                                                                                                                                                                                                 \*Improvement for total score of (a) and anxiety, depression, well-being, self-control, health, vitality subscores; \*improvement for vasomotor and somatic symptoms, sleep and menstrual problems, depression, anxiety, attraction, cognitive function scores and total score of (b); \*improvement for total score and vasomotor, emotional symptoms of (c), reduction of vasomotor from 48.8 ± 22.2 to 34.3 ± 26.3 (*P* = 0.0001)   Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Grady et al.,2009 \[[@B59]\]         \(a\) Diary of the frequency and severity of vasomotor symptoms; (b) Short Form 36 Health Survey; (c) Female Sexual Function Index   For high-dose group, 33% greater improvement for frequency of mild hot flush (*P* = 0.02); 67% reduction in the number of awake-sleep by hot flushes per week (*P* = 0.05); 16.2% more improvement for 50% reduction of hot flushes (*P* = 0.03)                                        */*                                                                                                                                                                                               In high-dosage group, 48% reduction for number of hot flushes per week, 67% reduction for number of awake sleep, and 47% for 50% reduction of frequency of hot flushes, respectively 37%, 58%, and 39% in low-dosage group, 37%, 44%, and 31% in placebo group                                                                                                                                                                         Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Chen et al.,2003 \[[@B60]\]          Greene Climacteric Scale                                                                                                             /                                                                                                                                                                                                                                                                                       \*Similar improvement for psychological (anxiety and depression), somatic and vasomotor subscores as well as total score (*P* \> 0.05); \*less improvement for sexual dysfunction (*P* \< 0.05)   Improvement for psychological, anxiety, depression, somatic and vasomotor subscores and total score (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                      Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *郑* Zheng et al.,2009 \[[@B61]\]    \(a\) Modified Kupperman Index; (b) Chinese Medical Symptoms Scale                                                                   Improvement for total scores of two scales (*P* \< 0.05)                                                                                                                                                                                                                                less reduction than TCM package for total scores of (a) and (b) (*P* \< 0.05)                                                                                                                     Improvement for (a) and (b) at weeks 8 and 12 (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                            Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *韦* Wei and Luo,2007 \[[@B62]\]     Modified Kupperman Index                                                                                                             /                                                                                                                                                                                                                                                                                       Similar for total score (*P* \> 0.05)                                                                                                                                                             Improvement for total score from 30.46 ± 6.84 to 8.26 ± 9.22 (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                                                             Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Qu et al.,2009 \[[@B63]\]            Hamilton Depression Scale                                                                                                            /                                                                                                                                                                                                                                                                                       \*No significant difference for total score (*P* \> 0.05); \*inimitably improved insomnia middle and anxiety (somatic), no improvement for work and activities, agitation                         Improvement for depressed mood, feeling of guilt, suicide, insomnia early, insomnia middle, anxiety (psychological and somatic) subscores (*P* \< 0.05)                                                                                                                                                                                                                                                                                Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Chang et al., 2012 \[[@B64]\]        Kupperman menopause Index                                                                                                            Magnificently improved vasomotor, numbness and tingling, insomnia, nervousness, feeling blue and depressed, dizzy spells, tired feelings, rheumatic pain, sensation of crawling on the skin, vaginal dryness (*P* \< 0.01), no improvement for headache and palpitation (*P* \> 0.05)   /                                                                                                                                                                                                 Improvement for all subscales at week 12 (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                                 Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Kim et al., 2012 \[[@B65]\]          \(a\) Kupperman Index; (b) Menopause Rating Scale                                                                                    \*Better for hot flash subscore (*P* = 0.046) and total score of (a) (*P* = 0.032); \*significant reduction for total score (*P* = 0.035) but no improvement for hot flash of (b) (*P* = 0.121)                                                                                         /                                                                                                                                                                                                 \*Improvement for total score of (a) from 18.93 ± 11.28 to 13.32 ± 10.15 (*P* = 0.021), hot flash from 5.25 ± 3.59 to 3.51 ± 2.36 (*P* = 0.032); \*improvement for total score of (b) from 12.45 ± 8.79 to 8.32 ± 6.75 (*P* = 0.027), hot flash from 1.85 ± 1.15 to 1.10 ± 0.79 (*P* = 0.096)                                                                                                                                          Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Hsu et al.,2011 \[[@B66]\]           Greene Climacteric Scale                                                                                                             More improvement for feeling tense or nervous (*P* = 0.07), insomnia (*P* = 0.004), excitable (*P* = 0.047), musculoskeletal pain (*P* = 0.019) after 12 months                                                                                                                         /                                                                                                                                                                                                 More than 90% improvement in almost all parameters (except sexual function) at months 6 and 12                                                                                                                                                                                                                                                                                                                                         Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Kwee et al.;2007 \[[@B67]\]          \(a\) Diary for frequency of vasomotor symptoms; (b) Short Form 36 Health Survey                                                     Improvement for hot flushes with 29% greater average score, more efficacy for weeks 5, 7--11 (*P* \< 0.05)                                                                                                                                                                              \*Less improvement for hot flushes with 50% average score, especially at weeks 4--13 (*P* \< 0.01); \*no improvement for hot flush reduction of (b)                                               Improvement for score of (a) at weeks 5, 7--11, no improvement for (a) and (b) at week 16                                                                                                                                                                                                                                                                                                                                              Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *陈* Chen et al.,2005 \[[@B68]\]     Modified Kupperman Index                                                                                                             */*                                                                                                                                                                                                                                                                                     Similar improvement for hot flush score and total score (*P* \> 0.05)                                                                                                                             Improvement for total score from 25.05 ± 8.01 to 8.73 ± 6.06                                                                                                                                                                                                                                                                                                                                                                           Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *楼* Lou et al.,2009 \[[@B69]\]      \(a\) Chinese Medical Symptoms Scale                                                                                                 More reduction for total scores of (a) (*P* \< 0.01)                                                                                                                                                                                                                                    */*                                                                                                                                                                                               Improvement for total score of (a) from 15.58 ± 3.45 to 5.66 ± 1.24 (*P* \< 0.01)                                                                                                                                                                                                                                                                                                                                                      Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *王* Wang et al.,2006 \[[@B70]\]     \(a\) Modified Kupperman Index; (b) Chinese Medical Symptoms Scale                                                                   \*More improvement for total score of (a) at 8th week (*P* \< 0.05) but not better at 12th week (*P* \> 0.05); \*better for total score of (b) at 8th and 12th weeks (*P* \< 0.05)                                                                                                      \*More improvement for total score of (a) and (b) (*P* \< 0.05)                                                                                                                                   ---                                                                                                                                                                                                                                                                                                                                                                                                                                    Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *吴* Wu et al.,2009 \[[@B71]\]       \(a\) Chinese Medical Symptoms Scale; (b) modified Kupperman Index                                                                   More improvement for total scores of (a) and (b) at week 8 (*P* \< 0.05)                                                                                                                                                                                                                */*                                                                                                                                                                                               ---                                                                                                                                                                                                                                                                                                                                                                                                                                    Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *李* Li et al.,2009 \[[@B72]\]       Kupperman Index                                                                                                                      */*                                                                                                                                                                                                                                                                                     Better for total score (*P* \< 0.01)                                                                                                                                                              Improvement for total score from 26.67 ± 5.02 to 20.36 ± 4.03 (*P* \< 0.01)                                                                                                                                                                                                                                                                                                                                                            Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *李* Li et al.,2008 \[[@B73]\]       Modified Kupperman Index                                                                                                             */*                                                                                                                                                                                                                                                                                     More reduction for total score (*P* \< 0.01)                                                                                                                                                      Improved total score from 26.05 ± 3.31 to 7.75 ± 2.851 (*P* \< 0.05)                                                                                                                                                                                                                                                                                                                                                                   Yes

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             

  *刘* Liu et al.,2011 \[[@B74]\]      \(a\) Number of hot flushes and sweat; (b) Chinese Medical Symptoms Scale; (c) Kupperman Index                                       \*More improvement for (a) (*P* \< 0.05), (b) (*P* \< 0.01), and (c) (*P* \< 0.01)                                                                                                                                                                                                      */*                                                                                                                                                                                               \*Reduction for number of hot flushes per day from 7.10 ± 2.06 to 2.20 ± 1.79 (*P* \< 0.05), number of sweats per day from 7.07 ± 1.87 to 2.13 ± 1.68 (*P* \< 0.05); \*improvement for total score of (b) from 26.67 ± 5.49 to 8.50 ± 3.51 (*P* \< 0.01); \*improvement for total score of (c) from 25.47 ± 5.45 to 6.80 ± 2.61 (*P* \< 0.01)                                                                                          Yes
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

\(c\)  

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                Adverse events/side effects                                                                                             Thickness of endometrium                            Zheng differentiation                          Prescriptions
  ------------------------------------ ----------------------------------------------------------------------------------------------------------------------- --------------------------------------------------- ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Hirata et al.,1997 \[[@B53]\]        Burping, gas, headache (similar to placebo)                                                                             No increase at 24 weeks, no difference to placebo   No                                             Dang gui (*Angelica sinensis*) root

                                                                                                                                                                                                                                                                  

  Woo et al.,2003 \[[@B54]\]           Urticaria                                                                                                               ---                                                 No                                             Ge gen (*Pueraria lobata*)

                                                                                                                                                                                                                                                                  

  Haines et al.,2008 \[[@B55]\]        Constipation, epigastric discomfort, hypercholesterolemia, per rectum bleeding (SAE) (no difference to placebo)         ---                                                 No                                             Dang gui (*Angelicae sinensis*) : huang qi (*Astragalus membranaceus*) = 1 : 5

                                                                                                                                                                                                                                                                  

  Davis et al.,2001 \[[@B56]\]         Abdominal bloating, lower abdominal pain and loose stools, headache, joint pain, dizziness (no difference to placebo)   ---                                                 No                                             Shu di huang (*Rehmannia glutinosa*) 15 g, shan zhu yu (*Cornus officinalis*) 10 g, shan yao (*Dioscorea opposita*) 12 g, ze xie (*Alisma orientalis*) 8 g, dan pi (*Paeonia suffruticosa*) 8 g, fu shen (*Poria cocos*) 12 g, chen pi (*Citrus reticulata*) 5 g, di gu pi (*Lycium chinensis*) 20 g, he huan pi (*Albizia julibrissin*) 15 g, suan zao ren (*Zizyphus jujuba*) 10 g, han lian cao (*Eclipta prostrata*) 15 g, and nu zhen zi (*Ligustrum lucidum*) 10 g

                                                                                                                                                                                                                                                                  

  Plotnikoff et al., 2012 \[[@B34]\]   Prevalent diarrhea (more than in placebo)                                                                               ---                                                 No                                             Rou gui (*Cinnamomum cassia Blume*), bai shao (*Paeonia lactiflora* Palls), tao ren (*Prunus persica*Batsch), fu ling (*Poria cocos Wolf*), and dan pi (*Paeonia suffruticosa*Andrews)

                                                                                                                                                                                                                                                                  

  Yasui et al.,2009 \[[@B57]\]         Diarrhea                                                                                                                ---                                                 No                                             *Angelica root*, *Atractylodis lanceae rhizome*, *Peony root*, *Bupleurum root*, *Hoelen*, *Glycyrrhiza root*, *Moutan bark*, *Gardenia fruit*, *Ginger rhizome,* and *Mentha herb*

                                                                                                                                                                                                                                                                  

  Wiklund et al.,1999 \[[@B58]\]       Headache/migraine, diarrhea/gastrointestinal system disorders, nausea, seven SAE (no difference to placebo)             No increase                                         No                                             Standardized extracts of ren shen (*Ginseng root*)

                                                                                                                                                                                                                                                                  

  Grady et al.,2009 \[[@B59]\]         Loose stools, vaginal bleeding, idiopathic pancreatitis (SAE) (no difference to placebo)                                No difference among three groups                    No                                             Ban zhi lian (*Herba Scutellaria barbata*) 30 g, shan dou gen (*Radix Sophora subprostratae*) 15 g, zhi mu (*Radix Anemarrhenae*) 12 g, hei dou (*Semen Glycine sojae*) 20 g, gan cao (*Radix Glycyrrhiza*) 8 g, da huang (*Rhizoma Rhei*) 8 g, fu xiao mai (*Fructus Tritici levis*) 15 g, huang qi (*Radix Astragali*) 12 g, sheng di huang (*Radix Rehmannia*) 12 g, nu zhen zi (*Fructus Ligustri lucidi*) 15 g, suan zao ren (*Semen Zyziphi spinozae*) 10 g, lian zi xin (*Plumula Nelumbinis*) 10 g, fu ling (*Poria Cocos*) 10 g, ze xie (*Rhizoma Alismatis*) 10 g, mu dan pi (*Cortex Moutan radicis*) 8 g, shan zhu yu (*Fructus Corni*) 10 g, huai niu xi (*Radix Achyranthis*) 10 g, mu li (*Concha Ostrea*) 12 g, tian men dong (*Radix Asparagi*) 12 g, ge gen (*Radix Pueraria*) 10 g, bai zhu (*Radix Atractylodis macrocephala*) 10 g, and yin yang huo (*Herba Epimedii*) 8 g

                                                                                                                                                                                                                                                                  

  Chen et al.,2003 \[[@B60]\]          Bloated abdomen, unusual vaginal bleeding, nausea and cough (no mention for the difference)                             ---                                                 No                                             Dang gui (*Angelicae Radix*) 4 g, bai zhu (*Atractylodis Rhizoma*) 4 g, bai shao (*Paeoniae Radix*) 4 g, chai hu (*Bupleuri Radix*) 4 g, fu ling (*Poria cocos Wolf*) 4 g, gan cao (*Glycyrrhizae Radix*) 2 g, mu dan pi (*Moutan Bark*) 2.5 g, zhi zi (*Gardeniae Fructus*) 2.5 g, gan jiang (*Zingiberis Rhizoma*) 4 g, and bo he (*Menthae Herba*) 2 g

                                                                                                                                                                                                                                                                  

  *郑* Zheng et al.,2009 \[[@B61]\]    Diarrhea (one case)                                                                                                     ---                                                 No                                             Huang lian (*Rhizoma Coptidis*), mai dong (*Radix Ophiopogonis*), mu dan pi (*Moutan Bark*), and other herbs

                                                                                                                                                                                                                                                                  

  *韦* Wei and Luo,2007 \[[@B62]\]     ---                                                                                                                     \(i\) No increase in treatment group\               No                                             Qian jin ba (*Moghania philippinensis*), ge jei (*Gekko gecko*), mei gui hua (*Rosa rugosa*), nuo dao gen (*Radix Oryzae Glutinosae*), and other herbs
                                                                                                                                                               (ii) Increase in hormone therapy group                                                             

                                                                                                                                                                                                                                                                  

  Qu et al.,2009 \[[@B63]\]            No serious side effect                                                                                                  ---                                                 No                                             Zhen zhu mu (*C. Margaritifera*) 15 g, suan zao ren (*Semen Z. Spinosae*) 8 g, bai zi ren (*Semen Platycladi*) 12 g, yuan zhi (*of  radix  polygalae*) 10 g, he huan pi (*cortex albiziae*) 8 g, huang qi (*radix astragali*) 15 g, xi yang shen (*radix codonopsis*) 10 g, shan yao (*radix dioscoreae*) 15 g, tu si zi (*semen cuscutae*) 15 g, and nv zhen zi (*fructus L. Lucidi*) 10 g

                                                                                                                                                                                                                                                                  

  Chang et al., 2012 \[[@B64]\]        No adverse events                                                                                                       ---                                                 No                                             *Cynanchum wilfordii, Phlomis umbrosa,* and *Angelica gigas*

                                                                                                                                                                                                                                                                  

  Kim et al., 2012 \[[@B65]\]          ---                                                                                                                     ---                                                 No                                             Hong shen (*red ginseng*)

                                                                                                                                                                                                                                                                  

  Hsu et al.,2011 \[[@B66]\]           No serious adverse events except soft stools, nausea (mild and transient) (no mention for the difference)               No increase                                         No                                             Shan yao (*Dioscorea alata*)

                                                                                                                                                                                                                                                                  

  Kwee et al.,2007 \[[@B67]\]          No serious adverse events                                                                                               ---                                                 Kidney yin deficiency                          Zhi mu (*Rhizoma Anemarrhenae*) 5.1%, huang bai (*Cortex Phellodendri*) 5.1%, shu di huang (*Radix Rehmanniae praeparata*) 20.5%, shan zhu yu (*Fructus Corni*) 10.3%, shan yao (*Rhizoma Dioscoreae oppositae*) 10.3%, fu ling (*Sclerotium Poriae albae*) 7.7%, duan long gu (*Os Draconis ustum*) 10.3%, duan mu li (*Concha Ostreae usta*) 10.3%, mu dan pi (*Cortex Moutan radicis*) 7.7%, and ze xie (*Rhizoma Alismatis*) 7.7%, and gou qi zi (*Fructus Lycii*) 5%---without details for the modification

                                                                                                                                                                                                                                                                  

  *陈* Chen et al.,2005 \[[@B68]\]     Gastrointestinal symptoms, breast distension and pain, and vaginal bleeding (no mention for the difference)             No increase                                         Yin deficiency with excessive fire             Shu di huang (*Radix Rehmanniae praeparata*), huang lian (*Rhizoma Coptidis*), bai shao (*Radix Paeoniae*), e jiao (*Colla Corii asini*), huang qin (*Radix Scutellariae*), and fu ling (*Poria*)

                                                                                                                                                                                                                                                                  

  *楼* Lou et al., 2009 \[[@B69]\]     No serious side effect                                                                                                  No increase                                         Yin deficiency with excessive fire             Yin yang huo (*Herba Epimedii*), other herbs (without details)

                                                                                                                                                                                                                                                                  

  *王* Wang et al.,2006 \[[@B70]\]     No serious side effect                                                                                                  No increase                                         Kidney yin deficiency/kidney yang deficiency   Geng nian ning capsule: shu di huang (*Radix Rehmanniae praeparata*), fu ling (*Poria*), huang lian (*Rhizoma Coptidis*), e jiao (*Colla Corii asini*), other herbs bu shen oral liquid: shu di huang (*Radix Rehmanniae praeparata*), nu zhen zi (*Fructus Ligustri lucidi*), yin yang huo (*Herba Epimedi*), and other herbs (without details)

                                                                                                                                                                                                                                                                  

  *吴* Wu et al.,2009 \[[@B71]\]       Stomach disorder, breast distension (no difference to placebo)                                                          ---                                                 Yin deficiency with excessive liver qi         Bai shao (*Radix Paeoniae*), xiang fu (*Rhizoma Cyperi*), chuan lian zi (*Fructus Toosendan*), chai hu (*Radix Bupleuri*), and other six herbs

                                                                                                                                                                                                                                                                  

  *李* Li et al.,2009 \[[@B72]\]       No serious adverse events                                                                                               ---                                                 Spleen-kidney deficiency with blood stasis     Shan zhu yu (*Cornus officinalis*), lu jiao jiao (*Colla Cornus Cervi*), gui ban jiao (*Chinemys reevesii*), rou gui (*Cinnamomum cassia Blume*), ba ji tian (*Radix Morindae officinalis*), yin yang huo (*Herba Epimedi*), bai shao (*Radix Paeoniae*), san leng (*Rhizoma Sparganii Stoloniferi*), ze xie (*Rhizoma Alismatis*), shui zhi (*Hirude nipponica*Whitman), yu jin (*Curcuma aromatica Salisb*), gu sui bu (*Rhizoma Drynariae*), shan yao (*Dioscorea opposita*), and other herbs (without details)

                                                                                                                                                                                                                                                                  

  *李* Li et al.,2008 \[[@B73]\]       Headache, dizziness, epigastric discomfort (no difference to vitamin E plus oryzanol treatment)                         ---                                                 Yin deficiency with excessive fire             Sheng di huang (*Radix Rehmannia*) 30 g, shan zhu yu (*Cornus officinalis*) 15 g, nu zhen zi (*fructus L. Lucidi*) 15 g, han lian cao (*Eclipta prostrata*) 15 g, gou qi zi (*Fructus Lycii*) 15 g, tu si zi (*semen cuscutae*) 15 g, dan shen (*Salvia miltiorrhiza*) 15 g, di gu pi (*Lycium chinensis*) 15 g, gui ban (*Carapax Testudinis*) 15 g, zhen zhu mu (*C. Margaritifera*) 15 g, wu wei zi (*Schisandra chinensis*) 10 g, yuan zhi (*Radix Polygalae*) 10 g, and yin yang huo (*Herba Epimedi*)10 g

                                                                                                                                                                                                                                                                  

  *刘* Liu et al.,2011 \[[@B74]\]      ---                                                                                                                     ---                                                 Yin deficiency with excessive fire             Gou teng (*Gambir Plant*)15 g, lian zi xin (*Plumula Nelumbinis*) 5 g, huang lian (*Rhizoma Coptidis*) 3 g, suan zao ren (*Semen Z. Spinosae*) 15 g, fu xiao mai (*Fructus Tritici levis*) 30 g, dan shen (*Salvia Miltiorrhiza*) 10 g, sheng di huang (*Radix Rehmannia*) 10 g, and shan zhu yu (*Fructus Corni*) 9 g
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Quality of the included studies.

  Source (author, year)                English/Chinese   Jadad scale score           
  ------------------------------------ ----------------- ------------------- --- --- -----
  Hirata et al.,1997 \[[@B53]\]        English           2                   1   1   4
  Woo et al.,2003 \[[@B54]\]           English           1                   1   1   3
  Haines et al.,2008 \[[@B55]\]        English           2                   2   1   5
  Davis et al.,2001 \[[@B56]\]         English           2                   2   1   5
  Plotnikoff et al., 2012 \[[@B34]\]   English           2                   1   1   4
  Yasui et al., 2009 \[[@B57]\]        English           1                   0   1   2
  Wiklund et al.,1999 \[[@B58]\]       English           1                   2   1   4
  Grady et al.,2009 \[[@B59]\]         English           2                   2   1   5
  Chen et al.,2003 \[[@B60]\]          English           1                   0   1   2
  Qu et al.,2009 \[[@B63]\]            English           2                   0   0   2
  Chang et al., 2012 \[[@B64]\]        English           2                   1   1   4
  Kim et al., 2012 \[[@B65]\]          English           2                   1   1   4
  Hsu et al.,2011 \[[@B66]\]           English           1                   2   0   3
  Kwee et al.,2007 \[[@B67]\]          English           2                   2   1   5
                                                                                     
  Mean score                           /                 /                   /   /   3.7
                                                                                     
  *郑* Zheng et al.,2009 \[[@B61]\]    Chinese           2                   0   0   2
  *韦* Wei and Luo,2007 \[[@B62]\]     Chinese           2                   0   0   2
  *陈* Chen et al.,2005 \[[@B68]\]     Chinese           1                   1   1   3
  *楼* Lou et al.,2009 \[[@B69]\]      Chinese           2                   2   0   4
  *王* Wang et al.,2006 \[[@B70]\]     Chinese           2                   2   0   4
  *吴* Wu et al.,2009 \[[@B71]\]       Chinese           2                   2   0   4
  *李* Li et al.,2009 \[[@B72]\]       Chinese           2                   0   1   3
  *李* Li et al.,2008 \[[@B73]\]       Chinese           2                   0   0   2
  *刘* Liu et al.,2011 \[[@B74]\]      Chinese           1                   0   0   1
                                                                                     
  Mean score                           /                 /                   /   /   2.8
  Total mean score                     /                 /                   /   /   3.3

[^1]: Academic Editor: V. C. N. Wong
